BerGenBio ASA announced the appointment of Olav Hellebø as the CEO. Mr. Hellebø, who brings three decades of experience in the pharmaceutical and biotechnology industries, is set to assume the position on November 21, 2024.
Company Information
Company
BerGenBio ASA
Location
Bergen, Vestland, Norway
About
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.
Fundz sees it the moment BerGenBio ASA changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BergenBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma